|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase I and pharmacokineticstudy of ABI- 007,a cremophorfree,protein-stabilized,nanoparticleformulation of paclitaxel 显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，5： | 1 |
| 2 | Development of a biochemotherapy regimen with concurrent,administration of cisplation,vinblastine,dacarbazine,interferon alfa,and interleukin-2 for patients with metastatic melanoma显示文摘 | Legha SS Ring S Eton O | 1998 | J Clin Oncol1998，16，5： | 1 |
| 3 | Phase I and pharmaeokinetic study of ABI - 007, a Cremophor - free, protein - stabilized, nanoparticle formulation of paclitaxel显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clinical Cancer Res2002，8，： | 1 |
| 4 | Phase Ⅰ and pharmacokinetic study of ABI-007, a Cremophor-free, protein- stabilized, nanoparticle formulation of paclitaxel显示文摘 | IBRAHIM NK DESAI N LEGHA S | 2002 | Clin Cancer Res2002，8，5： | 1 |
| 5 | Phase I and pharmacokinetic study of ABI-007, a cremophor- free, protein-stabilized, nanoparticle formulation of paclitaxel 显示文摘 | IBRAHIM N K DESAI N LEGHA S | 2002 | Clin Cancer Res2002，，8： | 1 |
| 6 | Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy显示文摘 | Legha S S | 1997 | Seminars in Oncology1997，24，4： | 1 |
| 7 | Phase I and pharmaco- kinetic study of ABI-007, a Cremophor-free proteinstabilized, nanoparticle formulation of paclitaxel 显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，5： | 1 |
| 8 | Development of a biochemotherapy regimen with concurrent ainistration of cisplatin,vinblastine,dacarbazine,interferon alfa,and interleukin-2 for patients with metastatic melanoma显示文摘 | LEGHA S S RING S ETON O | 1998 | J Clin Oncol1998，16，5： | 1 |
| 9 | Phase I and pharmaeo - ki- netic study of ABI - 007, a Cremophor - free, protein - stabilized, nanoparticle formulation of paelitaxel显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Cliii Cancer Res2002，8，： | 1 |
| 10 | Phase Ⅰ and pharmacokinetic study of ABI-007,a cremophor-free,protein-stabilized,nanoparticle formulation of paclitaxel显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，5： | 1 |
| 11 | A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma 显示文摘 | Legha S S Ring S Papadoponlos N | 1989 | Cancer1989，64，10： | 1 |
| 12 | Results of interleukin-2- based treatment in advanced melanoma: a ease record-based analysis of 631 patients 显示文摘 | Keilholz V Conradt C Legha S S | 1998 | J Clin Oneol1998，16，9： | 1 |
| 13 | Phase I and pharmacoki- netic study of ABI - 007, a Cremophor - free, protein - stabilized, nanoparticle formulation of paclitaxel显示文摘 | Ibrahim N K Desai N Legha S | 2002 | Clinical Cancer Research2002，，8： | 1 |
| 14 | A phase Ⅱ trial of taxol in metastatic melanoma显示文摘 | Legha SS Ring S Papadopoulos N | 1990 | Cancer1990，65，11： | 1 |
| 15 | Phase I andpharmacokinetic study of ABI-007,a Cremophor-free,protein-stabilized ,nanoparticle formulation of paclitaxel 显示文摘 | Ibrahim NK Desai N Legha S | 2002 | ClinCancer Res2002，8，5： | 1 |
| 16 | Prognostic factors in metastatic breast cancer treated with combination chemotherapy显示文摘 | SWENERTON K D LEGHA S S SMITH T | 1979 | Cancer Res1979，39，5： | 1 |
| 17 | Phase I and pharmacokinetic study of ABI-007,a Cremophor-fi'ee,protein-stabilized,nanoparticle formulation ofpaclitaxel显示文摘 | lbrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，05： | 1 |
| 18 | Phase I and pharmacokinetic study of ABI-007, a cremophor free, protein stabi- lized, nanoparticle formulation of paelitaxel显示文摘 | Ibrahim N K Desai N Legha S | 2002 | Clinical Cancer Research2002，8，5： | 1 |
| 19 | Phase I and pharma- cokinetic study of ABI-007, a Cremophor-free, protein - stabilized, nanoparticle formulation of Paclitaxel 显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，5： | 1 |
| 20 | Phase I and pharmacokinetic study of ABI-007, a Cremophor free, protein-stabilized, nanoparticle formulation of paclitaxel显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员